ClinicalTrials.gg
CompletedNCT05077982Updated Apr 12, 2023

The Long Term Effects of COVID on Pulmonary Function

An observational study in Covid19, COVID-19 Pneumonia and Critical Illness, sponsored by Sciberras, Stephen M.D.. Completed at 2 sites in Malta. Open to participants aged 18 Years to 95 Years. Per ClinicalTrials.gov, last updated 2023-04-12.

Sponsored by Sciberras, Stephen M.D. · Observational

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
123
Ages
18 Years to 95 Years
Sex
All
01

Study summary

An observational cohort study of patients discharged from the ICU following admission with COVID19 infection, looking at their medical wellbeing 6 months after discharge from the ICU.

Read the detailed description

The COVID-19 epidemic has placed an unprecedented strain on medical services worldwide. Throughout 2020 and early 2021, hospitals and their critical care services have been inundated with patients suffering from critical illness due to COVID-19, some of whom developed multi-organ failure and required a prolonged ICU stay. While the medical literature is now replete with publications and research on the acute phase of illness due to COVID-19, including critical illness, there is a paucity of studies detailing the long-term outcomes following COVID-19 critical illness.

While the negative long-term physical health, mental health and quality-of-life related effects of ARDS have been well documented, there has been very little long-term COVID-19 ARDS specific outcome studies published.

This is an observational cohort study that aims to assess the long-term health outcomes of adult patients admitted to Mater Dei Hospital Intensive Care Unit with COVID-19 infection. Patients will initially be assessed at 6 months after discharge from ITU. They will be interviewed by trained researchers using validated questionnaires. These questionnaires will assess their physical health, mental health and functional status. Participants will be examined and asked to do a 6minute walk test also using validated non-invasive physical assessment tools. They will be offered pulmonary function tests to be carried out at the Pulmonary function laboratory.

02

Conditions studied

  • Covid19
  • COVID-19 Pneumonia
  • Critical Illness
  • Quality of Life

Keywords

  • Covid19
  • Critical Illness
03

In context

COVID-19

7,990 studies on the registry are indexed under COVID-19; 466 are open to participants now.

This study's enrollment of 123 is below the median of 268 across 3,208 observational studies indexed under COVID-19.

Browse COVID-19 studies →

Lead sponsor

Sciberras, Stephen M.D. is the lead sponsor of 4 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 95 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All patients will be included

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All patients admitted to the Intensive Care Unit with organ failure secondary to acute COVID-19 infection and successfully discharged from Mater Dei Hospital and surviving beyond 6 months after discharge, will be offered inclusion in the study.

A positive COVID PCR result before or during the patient's admission will be necessary for inclusion in the study. Participants will be over 18 years of age, with no restriction as regards race, ethnicity or gender.

Exclusion criteria

Exclusion Criteria:

  • There are no exclusion criteria
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
123 participants (actual)
Patient registry
No

Interventions

  • Diagnostic testSpirometry

    Spirometry to assess lung function

  • Diagnostic test6-minute walk

    Exercise tolerance

06

What researchers measure

Primary outcomes

  1. Long term general health effects of critical illness due to COVID-19 infection

    Observation of the effect critical illness due to COVID-19 has on a patients' health related quality of life at 6 and 12 months after discharge from the ICU

    Time frame: at 6 months

  2. Long term general health effects of critical illness due to COVID-19 infection

    Observation of the effect critical illness due to COVID-19 has on a patients' health related quality of life at 6 and 12 months after discharge from the ICU

    Time frame: at 12 months

Secondary outcomes

  1. Correlation between severity of COVID19 illness and QOL

    Observation of how different severity of critical illness secondary to COVID-19 infection correlates with medium and long-term health related quality of life outcomes.

    Time frame: at 6 months

  2. Correlation between severity of COVID19 illness and QOL

    Observation of how different severity of critical illness secondary to COVID-19 infection correlates with medium and long-term health related quality of life outcomes.

    Time frame: at 12 months

07

Study locations

2 sites
  • Mater Dei Hospital
    Imsida, MSD2090, Malta
  • Mater Dei Hospital
    Imsida, Malta
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2021 to primary completion in Dec 2021, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 26, 2021
First posted
Oct 14, 2021
StartActual
Oct 15, 2021
Primary completionActual
Dec 31, 2021
CompletionActual
Jan 31, 2022
Last update
Apr 12, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 12, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05077982
Lead sponsor
Sciberras, Stephen M.D.
Collaborators
Mater Dei Hospital, Malta
Responsible party
Stephen Sciberras (Supervisor, Sciberras, Stephen M.D.) — Principal investigator
First posted
Oct 14, 2021
Start date
Oct 15, 2021
Primary completion
Dec 31, 2021
Completion
Jan 31, 2022
Last update
Apr 12, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion